Literature DB >> 27325846

Evidence-Based Versus Personalized Prostate Cancer Screening: Using Baseline Prostate-Specific Antigen Measurements to Individualize Screening.

Stacy Loeb1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27325846      PMCID： PMC5019765          DOI： 10.1200/JCO.2016.68.2138

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  22 in total

1.  Expected population impacts of discontinued prostate-specific antigen screening.

Authors:  Roman Gulati; Alex Tsodikov; Ruth Etzioni; Rachel A Hunter-Merrill; John L Gore; Angela B Mariotto; Matthew R Cooperberg
Journal:  Cancer       Date:  2014-07-25       Impact factor: 6.860

2.  Screening for Prostate Cancer Starting at Age 50-54 Years. A Population-based Cohort Study.

Authors:  Sigrid Carlsson; Melissa Assel; David Ulmert; Axel Gerdtsson; Jonas Hugosson; Andrew Vickers; Hans Lilja
Journal:  Eur Urol       Date:  2016-04-13       Impact factor: 20.096

3.  Reevaluating PSA Testing Rates in the PLCO Trial.

Authors:  Jonathan E Shoag; Sameer Mittal; Jim C Hu
Journal:  N Engl J Med       Date:  2016-05-05       Impact factor: 91.245

4.  Comparison of MR/ultrasound fusion-guided biopsy with ultrasound-guided biopsy for the diagnosis of prostate cancer.

Authors:  M Minhaj Siddiqui; Soroush Rais-Bahrami; Baris Turkbey; Arvin K George; Jason Rothwax; Nabeel Shakir; Chinonyerem Okoro; Dima Raskolnikov; Howard L Parnes; W Marston Linehan; Maria J Merino; Richard M Simon; Peter L Choyke; Bradford J Wood; Peter A Pinto
Journal:  JAMA       Date:  2015-01-27       Impact factor: 56.272

5.  Opportunistic testing versus organized prostate-specific antigen screening: outcome after 18 years in the Göteborg randomized population-based prostate cancer screening trial.

Authors:  Rebecka Arnsrud Godtman; Erik Holmberg; Hans Lilja; Johan Stranne; Jonas Hugosson
Journal:  Eur Urol       Date:  2014-12-31       Impact factor: 20.096

6.  Baseline prostate-specific antigen compared with median prostate-specific antigen for age group as predictor of prostate cancer risk in men younger than 60 years old.

Authors:  Stacy Loeb; Kimberly A Roehl; Jo Ann V Antenor; William J Catalona; Brian K Suarez; Robert B Nadler
Journal:  Urology       Date:  2006-01-25       Impact factor: 2.649

7.  Quantifying the role of PSA screening in the US prostate cancer mortality decline.

Authors:  Ruth Etzioni; Alex Tsodikov; Angela Mariotto; Aniko Szabo; Seth Falcon; Jake Wegelin; Dante DiTommaso; Kent Karnofski; Roman Gulati; David F Penson; Eric Feuer
Journal:  Cancer Causes Control       Date:  2007-11-20       Impact factor: 2.506

8.  Application of the 2013 American Urological Association early detection of prostate cancer guideline: who will we miss?

Authors:  Gregory B Auffenberg; Joshua J Meeks
Journal:  World J Urol       Date:  2014-06-20       Impact factor: 4.226

9.  Prostate specific antigen testing among the elderly--when to stop?

Authors:  Edward M Schaeffer; H Ballentine Carter; Anna Kettermann; Stacy Loeb; Luigi Ferrucci; Patricia Landis; Bruce J Trock; E Jeffrey Metter
Journal:  J Urol       Date:  2009-02-25       Impact factor: 7.450

10.  Strategy for detection of prostate cancer based on relation between prostate specific antigen at age 40-55 and long term risk of metastasis: case-control study.

Authors:  Andrew J Vickers; David Ulmert; Daniel D Sjoberg; Caroline J Bennette; Thomas Björk; Axel Gerdtsson; Jonas Manjer; Peter M Nilsson; Anders Dahlin; Anders Bjartell; Peter T Scardino; Hans Lilja
Journal:  BMJ       Date:  2013-04-15
View more
  2 in total

1.  Long-term survival of patients with thyroid cancer according to the methods of tumor detection: A nationwide cohort study in Korea.

Authors:  Yuh-Seog Jung; Chang-Mo Oh; Yeol Kim; Kyu-Won Jung; Junsun Ryu; Young-Joo Won
Journal:  PLoS One       Date:  2018-04-16       Impact factor: 3.240

2.  Potential Epigenetic Biomarkers for Prostate Cancer Screening.

Authors:  Jong-Myon Bae
Journal:  Int Neurourol J       Date:  2018-06-30       Impact factor: 2.835
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.